Logo image of MGTX

MEIRAGTX HOLDINGS PLC (MGTX) Stock Fundamental Analysis

NASDAQ:MGTX - Nasdaq - KYG596651029 - Common Stock - Currency: USD

5.42  -0.05 (-0.91%)

After market: 5.42 0 (0%)

Fundamental Rating

3

Taking everything into account, MGTX scores 3 out of 10 in our fundamental rating. MGTX was compared to 563 industry peers in the Biotechnology industry. Both the profitability and financial health of MGTX have multiple concerns. MGTX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MGTX had negative earnings in the past year.
MGTX had a negative operating cash flow in the past year.
In the past 5 years MGTX always reported negative net income.
MGTX had a negative operating cash flow in each of the past 5 years.
MGTX Yearly Net Income VS EBIT VS OCF VS FCFMGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of MGTX (-54.79%) is comparable to the rest of the industry.
The Return On Equity of MGTX (-217.89%) is worse than 70.34% of its industry peers.
Industry RankSector Rank
ROA -54.79%
ROE -217.89%
ROIC N/A
ROA(3y)-40.41%
ROA(5y)-32.41%
ROE(3y)-129.61%
ROE(5y)-91.21%
ROIC(3y)N/A
ROIC(5y)N/A
MGTX Yearly ROA, ROE, ROICMGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

Looking at the Gross Margin, with a value of 28.51%, MGTX is in the better half of the industry, outperforming 72.82% of the companies in the same industry.
MGTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGTX Yearly Profit, Operating, Gross MarginsMGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

MGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MGTX has been increased compared to 1 year ago.
The number of shares outstanding for MGTX has been increased compared to 5 years ago.
Compared to 1 year ago, MGTX has a worse debt to assets ratio.
MGTX Yearly Shares OutstandingMGTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MGTX Yearly Total Debt VS Total AssetsMGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MGTX has an Altman-Z score of -3.97. This is a bad value and indicates that MGTX is not financially healthy and even has some risk of bankruptcy.
MGTX has a Altman-Z score (-3.97) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.08 is on the high side and indicates that MGTX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.08, MGTX is doing worse than 78.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Altman-Z -3.97
ROIC/WACCN/A
WACC11.08%
MGTX Yearly LT Debt VS Equity VS FCFMGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MGTX has a Current Ratio of 2.03. This indicates that MGTX is financially healthy and has no problem in meeting its short term obligations.
MGTX has a Current ratio of 2.03. This is in the lower half of the industry: MGTX underperforms 74.96% of its industry peers.
MGTX has a Quick Ratio of 2.03. This indicates that MGTX is financially healthy and has no problem in meeting its short term obligations.
MGTX has a Quick ratio of 2.03. This is in the lower half of the industry: MGTX underperforms 73.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 2.03
MGTX Yearly Current Assets VS Current LiabilitesMGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.79% over the past year.
The Revenue has grown by 137.54% in the past year. This is a very strong growth!
MGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.15% yearly.
EPS 1Y (TTM)7.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
Revenue 1Y (TTM)137.54%
Revenue growth 3Y-4.07%
Revenue growth 5Y20.15%
Sales Q2Q%948.53%

3.2 Future

MGTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.37% yearly.
Based on estimates for the next years, MGTX will show a very strong growth in Revenue. The Revenue will grow by 100.92% on average per year.
EPS Next Y101.15%
EPS Next 2Y39.2%
EPS Next 3Y10.75%
EPS Next 5Y35.37%
Revenue Next Year1284.4%
Revenue Next 2Y306.33%
Revenue Next 3Y119.34%
Revenue Next 5Y100.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MGTX Yearly Revenue VS EstimatesMGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
MGTX Yearly EPS VS EstimatesMGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 221.41, the valuation of MGTX can be described as expensive.
Based on the Price/Forward Earnings ratio, MGTX is valued cheaper than 88.10% of the companies in the same industry.
MGTX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.42.
Industry RankSector Rank
PE N/A
Fwd PE 221.41
MGTX Price Earnings VS Forward Price EarningsMGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGTX Per share dataMGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.2%
EPS Next 3Y10.75%

More info and screens

0

5. Dividend

5.1 Amount

MGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEIRAGTX HOLDINGS PLC

NASDAQ:MGTX (5/9/2025, 4:05:06 PM)

After market: 5.42 0 (0%)

5.42

-0.05 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners43.64%
Inst Owner Change0.39%
Ins Owners4.28%
Ins Owner Change5.24%
Market Cap427.37M
Analysts83.64
Price Target24.07 (344.1%)
Short Float %5.17%
Short Ratio3.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.88%
Min EPS beat(2)-2.71%
Max EPS beat(2)12.47%
EPS beat(4)2
Avg EPS beat(4)-9.66%
Min EPS beat(4)-86.27%
Max EPS beat(4)37.88%
EPS beat(8)4
Avg EPS beat(8)-39.87%
EPS beat(12)4
Avg EPS beat(12)-35.62%
EPS beat(16)6
Avg EPS beat(16)-24.68%
Revenue beat(2)2
Avg Revenue beat(2)928.03%
Min Revenue beat(2)558.02%
Max Revenue beat(2)1298.04%
Revenue beat(4)2
Avg Revenue beat(4)416.49%
Min Revenue beat(4)-97.15%
Max Revenue beat(4)1298.04%
Revenue beat(8)3
Avg Revenue beat(8)199.99%
Revenue beat(12)5
Avg Revenue beat(12)121.32%
Revenue beat(16)9
Avg Revenue beat(16)148.14%
PT rev (1m)1.72%
PT rev (3m)64.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-640.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-96.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)195.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 221.41
P/S 12.84
P/FCF N/A
P/OCF N/A
P/B 6.3
P/tB 6.38
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)0.02
Fwd EY0.45%
FCF(TTM)-1.39
FCFYN/A
OCF(TTM)-1.33
OCFYN/A
SpS0.42
BVpS0.86
TBVpS0.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.79%
ROE -217.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.51%
FCFM N/A
ROA(3y)-40.41%
ROA(5y)-32.41%
ROE(3y)-129.61%
ROE(5y)-91.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.63%
Cap/Sales 14.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 2.03
Altman-Z -3.97
F-Score3
WACC11.08%
ROIC/WACCN/A
Cap/Depr(3y)233.72%
Cap/Depr(5y)368.57%
Cap/Sales(3y)147.08%
Cap/Sales(5y)142.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
EPS Next Y101.15%
EPS Next 2Y39.2%
EPS Next 3Y10.75%
EPS Next 5Y35.37%
Revenue 1Y (TTM)137.54%
Revenue growth 3Y-4.07%
Revenue growth 5Y20.15%
Sales Q2Q%948.53%
Revenue Next Year1284.4%
Revenue Next 2Y306.33%
Revenue Next 3Y119.34%
Revenue Next 5Y100.92%
EBIT growth 1Y-19.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year164.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y12.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.83%
OCF growth 3YN/A
OCF growth 5YN/A